Here we report the successful application of CEER to quantitate the total expression and the activation state of a number of RTKs including HER2 and other downstream signaling pathway proteins in several breast cancer cell lines, xenografts, and breast cancer clinical samples. This evidence concerns the gene ERBB2 and breast carcinoma.